Cited 18 times in
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2023-11-28T03:32:50Z | - |
dc.date.available | 2023-11-28T03:32:50Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196847 | - |
dc.description.abstract | Purpose: Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC). Patients and methods: Patients were 18 years and older with no previous systemic anticancer therapy. Neurologically stable patients with CNS metastases were allowed. Patients were randomly assigned 1:1 to lazertinib 240 mg once daily orally or gefitinib 250 mg once daily orally, stratified by mutation status and race. The primary end point was investigator-assessed progression-free survival (PFS) by RECIST v1.1. Results: Overall, 393 patients received double-blind study treatment across 96 sites in 13 countries. Median PFS was significantly longer with lazertinib than with gefitinib (20.6 v 9.7 months; hazard ratio [HR], 0.45; 95% CI, 0.34 to 0.58; P < .001). The PFS benefit of lazertinib over gefitinib was consistent across all predefined subgroups. The objective response rate was 76% in both groups (odds ratio, 0.99; 95% CI, 0.62 to 1.59). Median duration of response was 19.4 months (95% CI, 16.6 to 24.9) with lazertinib versus 8.3 months (95% CI, 6.9 to 10.9) with gefitinib. Overall survival data were immature at the interim analysis (29% maturity). The 18-month survival rate was 80% with lazertinib and 72% with gefitinib (HR, 0.74; 95% CI, 0.51 to 1.08; P = .116). Observed safety of both treatments was consistent with their previously reported safety profiles. Conclusion: Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / pathology | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Gefitinib / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / genetics | - |
dc.subject.MESH | Lung Neoplasms* / pathology | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Protein Kinase Inhibitors / adverse effects | - |
dc.title | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Jin Hyoung Kang | - |
dc.contributor.googleauthor | Ross A Soo | - |
dc.contributor.googleauthor | Thanyanan Reungwetwattana | - |
dc.contributor.googleauthor | James Chih-Hsin Yang | - |
dc.contributor.googleauthor | Irfan Cicin | - |
dc.contributor.googleauthor | Dong-Wan Kim | - |
dc.contributor.googleauthor | Yi-Long Wu | - |
dc.contributor.googleauthor | Shun Lu | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Yong-Kek Pang | - |
dc.contributor.googleauthor | Anastasia Zimina | - |
dc.contributor.googleauthor | Chin Heng Fong | - |
dc.contributor.googleauthor | Elena Poddubskaya | - |
dc.contributor.googleauthor | Ahmet Sezer | - |
dc.contributor.googleauthor | Soon Hin How | - |
dc.contributor.googleauthor | Pongwut Danchaivijitr | - |
dc.contributor.googleauthor | YuKyung Kim | - |
dc.contributor.googleauthor | Yeji Lim | - |
dc.contributor.googleauthor | Taewon An | - |
dc.contributor.googleauthor | Hana Lee | - |
dc.contributor.googleauthor | Hae Mi Byun | - |
dc.contributor.googleauthor | Bojan Zaric | - |
dc.identifier.doi | 10.1200/JCO.23.00515 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 37379502 | - |
dc.identifier.url | https://ascopubs.org/doi/10.1200/JCO.23.00515 | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 41 | - |
dc.citation.number | 26 | - |
dc.citation.startPage | 4208 | - |
dc.citation.endPage | 4217 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.41(26) : 4208-4217, 2023-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.